Skip to content

Research on the Development of Early Diagnostic Markers for Gynecological Tumors Based on PhIP-Seq Technology

Research on the Development of Early Diagnostic Markers for Gynecological Tumors Based on PhIP-Seq Technology

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108639
Enrollment
Unknown
Registered
2025-09-02
Start date
2025-09-02
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer, endometrial cancer, cervical cancer

Interventions

Index test:PhIP-Seq test

Sponsors

Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. >=18 years old; 2. Those who are admitted to the hospital for ovarian masses, cervical masses or endometrial masses and need surgery; 3. There are remaining blood samples during the diagnosis and treatment process;

Exclusion criteria

Exclusion criteria: 1. History of radiotherapy, chemotherapy, targeted therapy, etc.; 2. History of malignant tumors; 3. Pregnancy; 4. Refusal to enroll; 5. The primary tumor is not ovarian, endometrium, or cervical tissue; 6. Combined with other malignant diseases; 7. Combined with a variety of chronic diseases such as hypertension, diabetes and autoimmune diseases;

Design outcomes

Primary

MeasureTime frame
Autoantibody;

Countries

China

Contacts

Public ContactJinyi Tong

Affiliated hangzhou first people's hospital, zhejiang university school of medicine

tongjinyi252@zju.edu.cn+86 571 56005077

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026